Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid

Luna, MS; Manzoni, P; Paes, B; Baraldi, E; Cossey, V; Kugelman, A; Chawla, R; Dotta, A; Fernández, RR; Resch, B; Carbonell-Estrany, X.
Expert consensus on palivizumab use for respiratory syncytial virus in developed countries.
Paediatr Respir Rev. 2018;
PubMed FullText FullText_MUG

 

Authors Med Uni Graz:
Resch Bernhard
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early childhood and palivizumab is the only licensed intervention for prevention. Palivizumab guidelines should reflect the latest evidence, in addition to cost-effectiveness and healthcare budgetary considerations. RSV experts from Europe, Canada and Israel undertook a systematic review of the evidence over the last 5 years and developed recommendations regarding prophylaxis in industrialised countries. Almost 400 publications were reviewed. This group recommended palivizumab for: preterm infants (<29 and ≤31 weeks gestational age [wGA] and ≤9 and ≤6 months of age, respectively; high-risk 32-35wGA), former preterm children ≤24 months with chronic lung disease/bronchopulmonary dysplasia, children ≤24 months with significant congenital heart disease; and other high-risk populations, such as children ≤24 months with Down syndrome, pulmonary/neuromuscular disorders, immunocompromised, and cystic fibrosis. Up to 5 monthly doses should be administered over the RSV season. It is our impression that the adoption of these guidelines would help reduce the burden of RSV. Copyright © 2018 Elsevier Ltd. All rights reserved.

© Meduni GrazImprint